Learn Medical Billing Process, Tips to best AR Specialist. Medical Insurance Billing codes, Denial, procedure code and ICD 10, coverage guidelines. Demographic, charge, payment entry, AR process and eligibility and follow up. How to Guide.
Pages
- Home
- Medical Billing Question and Answer - Terms
- Insurance Denial Claim Appeal Guidelines.
- Medical Billing Downloads
- Understand Medical Billing
- Medical Billing Outsource
- Medicare Coverage and Plan Overview
- Advertise with us
- EVALUATION AND MANAGEMENT CPT code [99201-99499] - Full List
- Overall Medical billing process
- CPT Code 99201, 99202, 99203, 99204, 99205 - Which code to USE
- Internal Medical Billing Audit - how to do

CPT CODE J3489, J9310, J9201
Group 1 Codes:
J3489 INJECTION, ZOLEDRONIC ACID, 1 MG
Coverage Indications, Limitations, and/or Medical Necessity
Indications
Zoledronic acid is indicated for the treatment of:
Acute Hypercalcemia of malignancy;
Multiple myeloma;
Bone metastases from solid tumors in conjunction with standard antineoplastic therapy, including bone metastases from multiple myeloma, breast carcinoma, prostate carcinoma, and other solid tumors. Note: Prostate cancer should have progressed after treatment with at least one hormonal therapy;
Drug-induced osteopenia, secondary to androgen-deprivation therapy in prostate cancer patients (prophylaxis);
Cancer treatment-induced bone loss in breast cancer;
Pagets disease;
Post-Menopausal (Senile) Osteoporosis;
Osteoporosis in men; and
Glucocorticoid - induced osteoporosis in patients expected to be on glucocorticoids for at least 12 months (Effective 3/13/2009).
Limitations
The safety and efficacy of zoledronic acid in the treatment of hypercalcemia associated with hyperparathyroidism or with other non-tumor-related conditions has not been established.
Osteonecrosis of the jaw has been reported. All patients should have a routine oral exam prior to treatment.
ICD-10 CODE DESCRIPTION
C00.0 - C43.9 - Opens in a new window Malignant neoplasm of external upper lip - Malignant melanoma of skin, unspecified
C4A.0 - C4A.9 - Opens in a new window Merkel cell carcinoma of lip - Merkel cell carcinoma, unspecified
C44.00 - C49.9 - Opens in a new window Unspecified malignant neoplasm of skin of lip - Malignant neoplasm of connective and
soft tissue, unspecified
C50.011 - C75.9 - Opens in a new window Malignant neoplasm of nipple and areola, right female breast - Malignant neoplasm of
endocrine gland, unspecified
C7A.00 - C7B.8 - Opens in a new window Malignant carcinoid tumor of unspecified site - Other secondary neuroendocrine tumors
C76.0 - C79.9 - Opens in a new window Malignant neoplasm of head, face and neck - Secondary malignant neoplasm of
unspecified site
C80.0 - C84.79 - Opens in a new window Disseminated malignant neoplasm, unspecified - Anaplastic large cell lymphoma, ALK-
negative, extranodal and solid organ sites
C84.A0 - C84.Z9 - Opens in a new window Cutaneous T-cell lymphoma, unspecified, unspecified site - Other mature T/NK-cell
lymphomas, extranodal and solid organ sites
C84.90 - C84.99 - Opens in a new window Mature T/NK-cell lymphomas, unspecified, unspecified site - Mature T/NK-cell
lymphomas, unspecified, extranodal and solid organ sites
C85.10 - C86.6 - Opens in a new window Unspecified B-cell lymphoma, unspecified site - Primary cutaneous CD30-positive T-
cell proliferations
C88.2 - C91.62 - Opens in a new window Heavy chain disease - Prolymphocytic leukemia of T-cell type, in relapse
C91.A0 - C91.Z2 - Opens in a new window Mature B-cell leukemia Burkitt-type not having achieved remission - Other lymphoid
leukemia, in relapse
C91.90 - C91.92 - Opens in a new window Lymphoid leukemia, unspecified not having achieved remission - Lymphoid leukemia,
unspecified, in relapse
C92.00 - C92.62 - Opens in a new window Acute myeloblastic leukemia, not having achieved remission - Acute myeloid leukemia
with 11q23-abnormality in relapse
C92.A0 - C92.Z2 - Opens in a new window Acute myeloid leukemia with multilineage dysplasia, not having achieved remission -
Other myeloid leukemia, in relapse
C92.90 - C92.92 - Opens in a new window Myeloid leukemia, unspecified, not having achieved remission - Myeloid leukemia,
unspecified in relapse
C93.00 - C93.32 - Opens in a new window Acute monoblastic/monocytic leukemia, not having achieved remission - Juvenile
myelomonocytic leukemia, in relapse
C93.Z0 - C93.Z2 - Opens in a new window Other monocytic leukemia, not having achieved remission - Other monocytic leukemia,
in relapse
C93.90 - C93.92 - Opens in a new window Monocytic leukemia, unspecified, not having achieved remission - Monocytic leukemia,
unspecified in relapse
C94.00 - C94.32 - Opens in a new window Acute erythroid leukemia, not having achieved remission - Mast cell leukemia, in
relapse
C94.80 - C96.4 - Opens in a new window Other specified leukemias not having achieved remission - Sarcoma of dendritic cells
(accessory cells)
C96.A - C96.Z - Opens in a new window Histiocytic sarcoma - Other specified malignant neoplasms of lymphoid, hematopoietic
and related tissue
C96.9 Malignant neoplasm of lymphoid, hematopoietic and related tissue, unspecified
D03.0 - D03.9 - Opens in a new window Melanoma in situ of lip - Melanoma in situ, unspecified
D45 Polycythemia vera
E83.52 Hypercalcemia
M81.0 - M81.8 - Opens in a new window Age-related osteoporosis without current pathological fracture - Other osteoporosis
without current pathological fracture
M85.9 Disorder of bone density and structure, unspecified
M88.0 - M88.9 - Opens in a new window Osteitis deformans of skull - Osteitis deformans of unspecified bone
M89.9 Disorder of bone, unspecified
CPT/HCPCS Codes
J9310 INJECTION, RITUXIMAB, 100 MG
Coverage Indications, Limitations, and/or Medical Necessity
Indications
FDA:
Non-Hodgkin's Lymphoma (NHL).
Chronic Lymphocytic Leukemia (CLL).
Rheumatoid Arthritis (RA) in combination with methotrexate in adult patients with moderately- to severely-active RA who have inadequate response to one or more TNF antagonist therapies.
Wegener's Granulomatosis (WG) and Microscopic Polyangiitis (MPA) in adult patients in combination with glucocorticoids.
Off Label Use:
Waldenstrom's macroglobulinemia - relapsed or refractory
Thrombocytopenic purpura, immune or idiopathic
Renal transplant
prophylaxis - reduction of renal transplant rejection (pre and post) by reducing HLA/ABO antibodies in highly sensitized patients
acute rejection - reducing HLA/ABO antibodies
Pemphigus
Autoimmune hemolytic anemias
Acute Lymphoblastic Leukemia (ALL)
ICD-10 CODE DESCRIPTION
C82.00 - C84.79 - Opens in a new window Follicular lymphoma grade I, unspecified site - Anaplastic large cell lymphoma, ALK-
negative, extranodal and solid organ sites
C84.A0 - C84.Z9 - Opens in a new window Cutaneous T-cell lymphoma, unspecified, unspecified site - Other mature T/NK-cell
lymphomas, extranodal and solid organ sites
C84.90 - C84.99 - Opens in a new window Mature T/NK-cell lymphomas, unspecified, unspecified site - Mature T/NK-cell
lymphomas, unspecified, extranodal and solid organ sites
C85.10 - C88.0 - Opens in a new window Unspecified B-cell lymphoma, unspecified site - Waldenstrom macroglobulinemia
C88.4 Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue [MALT-lymphoma]
C91.00 - C91.01 - Opens in a new window Acute lymphoblastic leukemia not having achieved remission - Acute lymphoblastic
leukemia, in remission
C91.10 - C91.12 - Opens in a new window Chronic lymphocytic leukemia of B-cell type not having achieved remission - Chronic
lymphocytic leukemia of B-cell type in relapse
C91.40 Hairy cell leukemia not having achieved remission
C91.42 Hairy cell leukemia, in relapse
C96.0 - C96.4 - Opens in a new window Multifocal and multisystemic (disseminated) Langerhans-cell histiocytosis - Sarcoma
of dendritic cells (accessory cells)
C96.A - C96.Z - Opens in a new window Histiocytic sarcoma - Other specified malignant neoplasms of lymphoid, hematopoietic
and related tissue
C96.9 Malignant neoplasm of lymphoid, hematopoietic and related tissue, unspecified
D47.3 Essential (hemorrhagic) thrombocythemia
D59.0 - D59.1 - Opens in a new window Drug-induced autoimmune hemolytic anemia - Other autoimmune hemolytic anemias
D69.3 - D69.42 - Opens in a new window Immune thrombocytopenic purpura - Congenital and hereditary thrombocytopenia purpura
E88.01 Alpha-1-antitrypsin deficiency
G70.01 Myasthenia gravis with (acute) exacerbation
L10.0 - L10.9 - Opens in a new window Pemphigus vulgaris - Pemphigus, unspecified
L12.0 - L12.1 - Opens in a new window Bullous pemphigoid - Cicatricial pemphigoid
L12.8 - L12.9 - Opens in a new window Other pemphigoid - Pemphigoid, unspecified
M05.00 - M05.09 - Opens in a new window Felty's syndrome, unspecified site - Felty's syndrome, multiple sites
Group 1 Codes:
J9201 INJECTION, GEMCITABINE HYDROCHLORIDE, 200 MG
Coverage Indications, Limitations, and/or Medical Necessity
Indications
FDA:
Pancreatic cancer;
Non-small cell lung cancer;
Breast cancer;
Ovarian cancer
Off Label Use:
Bladder cancer - metastatic bladder (urothelial) cancer;
Uterine neoplasms, uterine sarcoma;
Head and neck cancers – cancer of the nasopharynx;
Hodgkins and non-Hodgkin’s lymphomas;
Germ cell tumors - ovarian;
Fallopian tube cancer;
Primary peritoneal cancer
Cancer of the thymus
ICD-10 CODE DESCRIPTION
C14.0 - C14.8 - Opens in a new window Malignant neoplasm of pharynx, unspecified - Malignant neoplasm of overlapping sites of lip, oral cavity and pharynx
C16.9 Malignant neoplasm of stomach, unspecified
C22.1 Intrahepatic bile duct carcinoma
C23 - C25.9 - Opens in a new window Malignant neoplasm of gallbladder - Malignant neoplasm of pancreas, unspecified
C33 - C37 - Opens in a new window Malignant neoplasm of trachea - Malignant neoplasm of thymus
C38.1 - C38.3 - Opens in a new window Malignant neoplasm of anterior mediastinum - Malignant neoplasm of mediastinum, part unspecified
C38.8 Malignant neoplasm of overlapping sites of heart, mediastinum and pleura
C45.1 Mesothelioma of peritoneum
C45.9 Mesothelioma, unspecified
C47.0 - C50.929 - Opens in a new window Malignant neoplasm of peripheral nerves of head, face and neck - Malignant neoplasm of unspecified site of unspecified male breast
C53.0 Malignant neoplasm of endocervix
C54.0 - C57.4 - Opens in a new window Malignant neoplasm of isthmus uteri - Malignant neoplasm of uterine adnexa, unspecified
C58 Malignant neoplasm of placenta
C62.00 - C62.92 - Opens in a new window Malignant neoplasm of unspecified undescended testis - Malignant neoplasm of left testis, unspecified whether descended or undescended
C65.1 - C67.9 - Opens in a new window Malignant neoplasm of right renal pelvis - Malignant neoplasm of bladder, unspecified
C68.9 Malignant neoplasm of urinary organ, unspecified
C75.3 Malignant neoplasm of pineal gland
Subscribe to:
Post Comments (Atom)
Medical Billing Popular Articles
-
CPT CODE AND Description 99391 - Periodic comprehensive preventive medicine reevaluation and management of an individual including an age...
-
Procedure CODES and Descriptions 99401 - Preventive medicine counseling and/or risk factor reduction intervention(s) provided to an indi...
-
CPT Code and description 99381 - Initial comprehensive preventive medicine evaluation and management of an individual including an age an...
-
When an ERA is received, providers may: •Post decision and payment information automatically, for individual claims included in an R...
-
Procedure code and Description 99251 Inpatient consultation for a new or established patient, which requires these 3 key components: A pro...
-
CPT code and description 80050 - General health panel This panel must include the following: Comprehensive metabolic panel (80053), ...
-
Medicare denial code and Descripiton 1 Deductible Amount 2 Coinsurance Amount 3 Co-payment Amount 4 The procedure code is inconsistent ...
-
93000-93010: Hone Your ECG Coding Skills With 3 Essential Pointers Whether you call them ECGs or EKGs, chances are you see a lot of elec...
-
Background: Type of Service (TOS) is an indicator that the contractor places on the Form CMS-1500 paper form or electronic format. The indic...
-
Billed amount: It is the Amount charged for each service performed by the provider. In other words it is the total charge value of the cla...

No comments:
Post a Comment